Regulatory T cells : hypes and limitations
(2008) In Current opinion in organ transplantation 13(4). p.8-333- Abstract
PURPOSE OF REVIEW: In recent years there has been increased interest in understanding the physiology and function of regulatory T cells. In this review we focus on the characterization of regulatory T-cell subsets and their potential therapeutic use in organ transplantation.
RECENT FINDINGS: Regulatory T cells can play an instrumental role in the establishment of operational tolerance to allografts. The level of expression and the extent of posttranslational acetylation of the regulatory T-cell specific transcription factor Foxp3 are important modulators of their suppressive activity. Low expression of CD127 can be used as a novel marker to define pure regulatory T-cell populations and the expression of CD45RA on CD4CD25... (More)
PURPOSE OF REVIEW: In recent years there has been increased interest in understanding the physiology and function of regulatory T cells. In this review we focus on the characterization of regulatory T-cell subsets and their potential therapeutic use in organ transplantation.
RECENT FINDINGS: Regulatory T cells can play an instrumental role in the establishment of operational tolerance to allografts. The level of expression and the extent of posttranslational acetylation of the regulatory T-cell specific transcription factor Foxp3 are important modulators of their suppressive activity. Low expression of CD127 can be used as a novel marker to define pure regulatory T-cell populations and the expression of CD45RA on CD4CD25 regulatory T cells characterizes a population with a more stable phenotype upon expansion in vitro. Interleukin-35 is a recently discovered immunosuppressive cytokine secreted by CD4CD25 regulatory T cells. Although the presence of allospecific memory T cells in the pretransplant period and the use of immunosuppressants might interfere with the effectiveness of regulatory T-cell-based therapies, encouraging results indicate that the immunosuppressive drug rapamycin does not affect the expansion and function of regulatory T cells and could be included in a combined therapy.
SUMMARY: Important advances have been made towards establishing regulatory T cells as a viable therapy in transplantation and the first clinical trials using human regulatory T cells are currently underway. There are, however, important limitations and safety issues that have to be addressed before this therapy can be fully translated into the clinic.
(Less)
- author
- Schiopu, Alexandru LU and Wood, Kathryn J
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- keywords
- Adoptive Transfer, Animals, Graft Rejection/immunology, Graft Survival/drug effects, Humans, Immunosuppressive Agents/therapeutic use, Organ Transplantation/adverse effects, T-Lymphocyte Subsets/drug effects, T-Lymphocytes, Regulatory/drug effects, Transplantation Tolerance, Transplantation, Homologous, Treatment Outcome
- in
- Current opinion in organ transplantation
- volume
- 13
- issue
- 4
- pages
- 8 - 333
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:18685326
- scopus:61649096596
- ISSN
- 1087-2418
- DOI
- 10.1097/MOT.0b013e3283061137
- language
- English
- LU publication?
- no
- id
- fca5c85c-3455-45bc-b1ab-a85af4769056
- date added to LUP
- 2023-03-10 12:18:19
- date last changed
- 2024-01-03 22:52:35
@article{fca5c85c-3455-45bc-b1ab-a85af4769056,
abstract = {{<p>PURPOSE OF REVIEW: In recent years there has been increased interest in understanding the physiology and function of regulatory T cells. In this review we focus on the characterization of regulatory T-cell subsets and their potential therapeutic use in organ transplantation.</p><p>RECENT FINDINGS: Regulatory T cells can play an instrumental role in the establishment of operational tolerance to allografts. The level of expression and the extent of posttranslational acetylation of the regulatory T-cell specific transcription factor Foxp3 are important modulators of their suppressive activity. Low expression of CD127 can be used as a novel marker to define pure regulatory T-cell populations and the expression of CD45RA on CD4CD25 regulatory T cells characterizes a population with a more stable phenotype upon expansion in vitro. Interleukin-35 is a recently discovered immunosuppressive cytokine secreted by CD4CD25 regulatory T cells. Although the presence of allospecific memory T cells in the pretransplant period and the use of immunosuppressants might interfere with the effectiveness of regulatory T-cell-based therapies, encouraging results indicate that the immunosuppressive drug rapamycin does not affect the expansion and function of regulatory T cells and could be included in a combined therapy.</p><p>SUMMARY: Important advances have been made towards establishing regulatory T cells as a viable therapy in transplantation and the first clinical trials using human regulatory T cells are currently underway. There are, however, important limitations and safety issues that have to be addressed before this therapy can be fully translated into the clinic.</p>}},
author = {{Schiopu, Alexandru and Wood, Kathryn J}},
issn = {{1087-2418}},
keywords = {{Adoptive Transfer; Animals; Graft Rejection/immunology; Graft Survival/drug effects; Humans; Immunosuppressive Agents/therapeutic use; Organ Transplantation/adverse effects; T-Lymphocyte Subsets/drug effects; T-Lymphocytes, Regulatory/drug effects; Transplantation Tolerance; Transplantation, Homologous; Treatment Outcome}},
language = {{eng}},
number = {{4}},
pages = {{8--333}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Current opinion in organ transplantation}},
title = {{Regulatory T cells : hypes and limitations}},
url = {{http://dx.doi.org/10.1097/MOT.0b013e3283061137}},
doi = {{10.1097/MOT.0b013e3283061137}},
volume = {{13}},
year = {{2008}},
}